Effect of Personalized Prebiotic and Probiotic Supplements on the Symptoms of Irritable Bowel Syndrome: An Open-Label, Single-Arm, Multicenter Clinical Trial

被引:2
|
作者
Matsuura, Nozomi [1 ]
Kanayama, Masaya [1 ]
Watanabe, Yuta [1 ]
Yamada, Hirokazu [2 ,3 ]
Lili, Loukia [4 ]
Torii, Akira [5 ]
机构
[1] Kirin Holdings Co Ltd, Inst Hlth Sci, Hlth Sci Business Div, Fujisawa, Kanagawa 2518555, Japan
[2] Soiken Inc, Tokyo, Tokyo 1010052, Japan
[3] EviPRO Co Ltd, Tokyo, Tokyo 1010032, Japan
[4] Thorne HealthTech Inc, New York, NY 10019 USA
[5] Torii Med Clin, Tokyo, Tokyo 1570066, Japan
关键词
irritable bowel syndrome; personalized; microbiome; prebiotics; probiotics; PLACEBO-RESPONSE RATE; DOUBLE-BLIND; GUT MICROBIOTA; SEVERITY; LACTOBACILLUS; JAPANESE;
D O I
10.3390/nu16193333
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background/Objectives: Prebiotics and probiotics have been reported to improve symptoms of irritable bowel syndrome (IBS). Nevertheless, the effects of prebiotics/probiotics can vary depending on the IBS subtypes. The purpose of this study was to investigate the effects of personalized prebiotic and probiotic supplements based on intestinal microbiota and IBS subtypes in patients. Methods: Patients with diarrhea-type IBS (IBS-D), constipation-type IBS (IBS-C), and mixed-type IBS (IBS-M) were enrolled (n = 40 per group; total: n = 120). Personalized prebiotic and probiotic supplements were determined according to the IBS subtypes and intestinal microbiota. The patients received supplements for 4 weeks. The primary outcome was the change in the IBS-severity scoring system from baseline to week 4. Results:The IBS-severity scoring system significantly decreased in all patients (-38.0 [95% confidence interval (CI): -53.6, -22.4]; p < 0.001), in patients with IBS-D (-44.5 [95% CI: -70.6, -18.5]; p = 0.004) and IBS-C (-51.2 [95% CI: -79.4, -22.9]; p = 0.002), but not in those with IBS-M (-20.0 [95% CI: -48.0, 8.1]; p = 0.47). In this study, no serious adverse events were observed that had a causal relationship with the intervention. Conclusions: In conclusion, personalized prebiotic and probiotic supplements selected according to individual intestinal microbiota and IBS subtype may alleviate the severity of IBS symptoms, particularly in patients with IBS-C and IBS-D.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Human Milk Oligosaccharides Support Normal Bowel Function and Improve Symptoms of Irritable Bowel Syndrome: A Multicenter, Open-Label Trial
    Palsson, Olafur S.
    Peery, Anne
    Seitzberg, Dorthe
    Amundsen, Ingvild Dybdrodt
    McConnell, Bruce
    Simren, Magnus
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2020, 11 (12) : e00276
  • [2] Collagenase Chemonucleolysis for Treating Cervical Disc Herniation: An Exploratory, Single-Arm, Open-Label, Multicenter Clinical Trial
    Wang, Zhijian
    Fan, Bifa
    Gu, Lili
    Zhang, Xuexue
    Sun, Tao
    Liu, Hui
    Li, Rongchun
    Wang, Likui
    Wang, Kaiqiang
    Li, Shun
    Ma, Yong
    You, Haibo
    Zhang, Daying
    PAIN AND THERAPY, 2025, 14 (01) : 217 - 235
  • [3] Efficacy and safety of peppermint oil for the treatment in Japanese patients with irritable bowel syndrome: a prospective, open-label, and single-arm study
    Matsueda, Kei
    Fukudo, Shin
    Ogishima, Masayuki
    Naito, Yuki
    Nakamura, Soichiro
    BIOPSYCHOSOCIAL MEDICINE, 2024, 18 (01)
  • [4] Efficacy and safety of peppermint oil for the treatment in Japanese patients with irritable bowel syndrome: a prospective, open-label, and single-arm study
    Kei Matsueda
    Shin Fukudo
    Masayuki Ogishima
    Yuki Naito
    Soichiro Nakamura
    BioPsychoSocial Medicine, 18
  • [5] Sirolimus treatment for intractable lymphatic anomalies: an open-label, single-arm, multicenter, prospective trial
    Ozeki, Michio
    Endo, Saori
    Yasue, Shiho
    Nozawa, Akifumi
    Asada, Ryuta
    Saito, Akiko M.
    Hashimoto, Hiroya
    Fujimura, Takumi
    Yamada, Yohei
    Kuroda, Tatsuo
    Ueno, Shigeru
    Watanabe, Shoji
    Nosaka, Shunsuke
    Miyasaka, Mikiko
    Umezawa, Akihiro
    Matsuoka, Kentaro
    Maekawa, Takanobu
    Hirakawa, Satoshi
    Furukawa, Taizo
    Fumino, Shigehisa
    Tajiri, Tatsuro
    Takemoto, Junkichi
    Souzaki, Ryota
    Kinoshita, Yoshiaki
    Fujino, Akihiro
    FRONTIERS IN MEDICINE, 2024, 11
  • [6] Efficacy of Jawarish Shahi a herbal formulation in irritable bowel syndrome: An open-labeled single-arm clinical trial
    Moazzam, Shehanshah Wali
    Mobeen, Abdul
    Siddiqui, Mansoor Ahmad
    JOURNAL OF TRADITIONAL AND COMPLEMENTARY MEDICINE, 2022, 12 (06): : 529 - 535
  • [7] Single-Arm Open-Label Clinical Trial of Two Grams of Aztreonam for the Treatment of Neisseria gonorrhoeae
    Barbee, Lindley A.
    Soge, Olusegun O.
    Ocbamichael, Negusse
    LeClair, Angela
    Golden, Matthew R.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (01)
  • [8] Prescript-Assist™ probiotic-prebiotic treatment for irritable bowel syndrome:: An open-label, partially controlled, 1-year extension of a previously published controlled clinical trial
    Bittner, Alvah C.
    Croffut, Robert M.
    Stranahan, Mary C.
    Yokelson, Titut N.
    CLINICAL THERAPEUTICS, 2007, 29 (06) : 1153 - 1160
  • [9] Effect of Open-label Placebo on Children and Adolescents With Functional Abdominal Pain or Irritable Bowel Syndrome A Randomized Clinical Trial
    Nurko, Samuel
    Saps, Miguel
    Kossowsky, Joe
    Zion, Sean Raymond
    Di Lorenzo, Carlo
    Vaz, Karla
    Hawthorne, Kelsey
    Wu, Rina
    Ciciora, Steven
    Rosen, John Michael
    Kaptchuk, Ted J.
    Kelley, John M.
    JAMA PEDIATRICS, 2022, 176 (04) : 349 - 356
  • [10] A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer
    Hasegawa, Hirotaka
    Shitara, Kohei
    Takiguchi, Shuji
    Takiguchi, Noriaki
    Ito, Seiji
    Kochi, Mitsugu
    Horinouchi, Hidehito
    Kinoshita, Takahiro
    Yoshikawa, Takaki
    Muro, Kei
    Nishikawa, Hiroyoshi
    Suna, Hideaki
    Kodera, Yasuhiro
    GASTRIC CANCER, 2022, 25 (03) : 619 - 628